Total Payments
$767.98
2018 Payments
$137.90
Companies
7
Transactions
51
Medicare Patients
921
Medicare Billing
$314,575
Payment Breakdown by Category
Food & Beverage$684.21 (89.1%)
Education$83.77 (10.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $684.21 | 48 | 89.1% |
| Education | $83.77 | 3 | 10.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $365.55 | 21 | $0 (2018) |
| PFIZER INC. | $115.41 | 15 | $0 (2017) |
| Incyte Corporation | $86.79 | 6 | $0 (2018) |
| Astellas Pharma US Inc | $74.74 | 2 | $0 (2017) |
| Janssen Biotech, Inc. | $65.54 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $48.40 | 3 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $11.55 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $137.90 | 9 | Novartis Pharmaceuticals Corporation ($98.12) |
| 2017 | $630.08 | 42 | Novartis Pharmaceuticals Corporation ($267.43) |
All Payment Transactions
51 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/02/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $11.46 | General |
| Category: Hematology/Oncology | ||||||
| 05/09/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $12.51 | General |
| Category: Hematology/Oncology | ||||||
| 03/07/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.81 | General |
| Category: Hematology/Oncology | ||||||
| 02/20/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $10.67 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2018 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2017 | PFIZER INC. | MYLOTARG (Drug), BOSULIF | Food and Beverage | In-kind items and services | $5.74 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2017 | PFIZER INC. | SUTENT (Drug), BAVENCIO | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 12/18/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/05/2017 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: Oncology | ||||||
| 10/23/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2017 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $11.55 | General |
| Category: Oncology | ||||||
| 10/10/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.85 | General |
| Category: Hematology/Oncology | ||||||
| 10/04/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $4.53 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/20/2017 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Food and Beverage | Cash or cash equivalent | $20.21 | General |
| Category: Oncology | ||||||
| 09/06/2017 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $29.82 | General |
| Category: Oncology | ||||||
| 08/23/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2017 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 211 | 1,692 | $374,191 | $121,882 |
| 2022 | 5 | 241 | 1,220 | $220,288 | $63,419 |
| 2021 | 4 | 131 | 765 | $60,725 | $36,505 |
| 2020 | 4 | 338 | 2,033 | $152,160 | $92,769 |
Total Patients
921
Total Services
5,710
Medicare Billing
$314,575
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 679 | $208,453 | $67,884 | 32.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 45 | 770 | $90,090 | $32,641 | 36.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 162 | $34,344 | $10,831 | 31.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 43 | $25,800 | $6,327 | 24.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 36 | 38 | $15,504 | $4,199 | 27.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 65 | 754 | $87,135 | $25,002 | 28.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 182 | $54,281 | $15,550 | 28.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 71 | 202 | $42,152 | $12,355 | 29.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 64 | 65 | $26,520 | $7,636 | 28.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 17 | $10,200 | $2,876 | 28.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 31 | 515 | $30,900 | $16,932 | 54.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 47 | 147 | $15,000 | $9,158 | 61.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 62 | $8,060 | $5,547 | 68.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 40 | 41 | $6,765 | $4,868 | 72.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 109 | 1,531 | $91,860 | $52,152 | 56.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 113 | 282 | $28,200 | $17,599 | 62.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 100 | 100 | $16,500 | $12,103 | 73.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 120 | $15,600 | $10,915 | 70.0% |
About Dr. Don Poster, D.O
Dr. Don Poster, D.O is a Hematology & Oncology healthcare provider based in Hollywood, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639191786.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Don Poster, D.O has received a total of $767.98 in payments from pharmaceutical and medical device companies, with $137.90 received in 2018. These payments were reported across 51 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($684.21).
As a Medicare-enrolled provider, Poster has provided services to 921 Medicare beneficiaries, totaling 5,710 services with total Medicare billing of $314,575. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Hollywood, FL
- Active Since 07/24/2006
- Last Updated 01/10/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1639191786
Products in Payments
- TASIGNA (Drug) $303.87
- JAKAFI (Drug) $86.79
- IBRANCE (Drug) $64.01
- IMBRUVICA (Drug) $42.45
- JADENU (Drug) $41.72
- SPRYCEL (Drug) $34.72
- DARZALEX (Biological) $23.09
- BOSULIF (Drug) $21.82
- SANDOSTATIN LAR (Drug) $19.96
- ELIQUIS (Drug) $18.84
- Xtandi (Drug) $14.75
- OPDIVO (Biological) $13.68
- FASLODEX (Drug) $11.55
- MYLOTARG (Drug) $5.74
- SUTENT (Drug) $5.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Hollywood
Atif Hussein, Md, MD
Hematology & Oncology — Payments: $17,186
Hematology & Oncology $17,186
Foluso Ogunsile, Md, MD
Hematology & Oncology — Payments: $11,266
Hematology & Oncology $11,266
Brian Hunis, Md, MD
Hematology & Oncology — Payments: $5,462
Hematology & Oncology $5,462
Alejandra Perez, Md, MD
Hematology & Oncology — Payments: $3,088
Hematology & Oncology $3,088
Ney Alves, Md, MD
Hematology & Oncology — Payments: $3,000
Hematology & Oncology $3,000
Michel Vulfovich, M.d, M.D
Hematology & Oncology — Payments: $1,588
Hematology & Oncology $1,588